PUBLICATIONS
Accuracy of substance exposure history in patients attending emergency departments after substance misuse: a comparison with biological sample analysis. Clinical Toxicology
Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England. Clinical Toxicology
Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act
Severe toxicity involving N-pyrrolidino etonitazene in the United Kingdom - a case report
Detection of flubromazolam in patients with suspected non-medical drug use attending emergency departments in the United Kingdom
Acute toxicity from the synthetic cathinone N-ethylpentylone (ephylone) in the United Kingdom
Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens
Effect of the UK Psychoactive Substances Act 2016 on episodes of toxicity related to new psychoactive substances as reported to the National Poisons Information Service. A time series analysis
Synthetic cannabinoid receptor agonists. Classification and nomenclature
Acute toxicity following analytically confirmed use of the Novel Psychoactive Substance (NPS) methiopropamine. A report from the Identification of Novel psychoActive substances (IONA) study
Human toxicity caused by indole and indazole carboxylate synthetic cannabinoid receptor agonists: from horizon scanning to notification
Clincial toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification of Novel psychoActive substances (IONA) study
Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service
CONFERENCE PRESENTATIONS/ABSTRACTS
Thomas SHL, Keating L, Bartley S, Rai SG, Hill SL, Hudson S. Cinical features associated with exposure to SL-164 in patients attending emergency departments in England. Clinical Toxicology 2022 (EAPCCT 2022)
Analytically-confirmed polydrug use is more common in drug misuse patients attending emergency departments in Scotland compared with those in England and Wales
Seven year trends in benzodiazepines detected in patients attending emergency departments in the United Kingdom after drug misuse
Clinical features associated with exposure to ADB-BUTINACA in patients attending emergency departments in England
Oteo A, Wright C, Hudson S, Thomas SHL. Changing patterns of synthetic cannabinoid receptor agonists in the United Kingdom emergency departments. Effects of national and international legislation. PHE Public Health Research and Science Conference 2021
Changing patterns of synthetic cannabinoid receptor agonists encountered in the United Kingdom emergency departments
Thomas SHL, Ketchin A, Issa S, Hill SL, Cooper J, Johnson G, Adeboye K, Eddleston M, Hudson S. Characteristics and clinical features of patients attending United Kingdom emergency departments with analytically-confirmed exposure to the synthetic cannabinoid MDMB-4en PINACA
Continuing low prevalence of analytically confirmed exposure to fentanyl and fentanyl analogues in patients with suspected severe heroin toxicity in the United Kingdom
Reduction in analytically confirmed exposure to new psychoactive substances in patients attending emergency departments with severe clinical toxicity in the United Kingdom
Analytically-confirmed exposure to N-ethylpentylone in the UK: a report from the IONA study
Analytically-confirmed exposure to a new psychoactive substances in patients with severe clinical toxicity in the UK, 2015-2018: a report from the IONA study
Thomas SHL. Changes with time in novel psychoactive substances identified in UK patients presenting with severe clinical toxicity. Oral presentation. PHE Public Health Research and Science Conference, Manchester 2019
Analytical prevalence of novel synthetic opioids including fentanyls in samples from patients presenting with apparent heroin overdose in the UK
Clinical toxicity from analytically confirmed exposure to the synthetic cathinone methylenedioxy-pyrrolidinohexiophenone (MDPHP) in the UK
Accuracy of patient exposure history compared with analytical findings for those reporting use of synthetic cannabinoid receptor agonists
Changes with time in analytically confirmed exposure to novel psychoactive substances (NPS) in patients with severe clinical toxicity in the UK
Analytically confirmed recreational use of oberacetam (Noopept) inthe UK
Analytical prevalence of drugs of misuse in homeless people presenting with severe toxicity after suspected use of novel psychoactive substances
Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine: a report from the Identification of Novel psychoActive substances (IONA) study
Changes with time in analytically confirmed exposure to novel psychoactive substances in patients with severe clinical toxicity in the UK
Synthetic cannabinoid receptor agonists identified in patients with severe clinical toxicity in England: a report from the Identification Of Novel psychoActive substances (IONA) study
Clinical features following analytically confirmed use of 5F-ADB, a synthetic cannabinoid receptor agonists. A report from the UK IONA study
Addressing the public health impact of new psychoactive substances: early analysis of the effects of the UK's Psychoactive Substances Act on poisons centre enquiries related to drugs of misuse
Analytically confirmed exposure to novel psychoactive substances in patients presenting to hospital with severe clinical toxicity in the United Kingdom. Results from the Identification Of Novel psychoActive substances (IONA) study
Convulsions associated with analytically confirmed phenibut ingestion
Patterns of presentation and clinical toxicity after reported use methiopropamine. A report from the UK National Poisons Information Service (NPIS)
Severe clinical toxicity after analytically confirmed use of the synthetic cannabinoid receptor against MDMB-CHMICA. A report from the Identification of Novel psychoActive substances (IONA) study
Toxicity following recreational use of synthetic cannabinoid receptor agonists and the impact of legal control measures. A report from the United Kingdom's National Poisons Information Service
Hill SL, Dunn M, Najafi J, Abouchedid R, Dargan PI, Wood DM, Thomas SHL. Identification of novel psychoactive substances in biological samples from patients with severe clinical toxicity in the UK. A report from the Identification of Novel psychoActive substances (IONA) study. Clinical Toxicology 2016; 54: p380
INCLUSION OF DATA IN OFFICAL REPORTS
Advisory Council on the Misuse of Drugs. Report - Synthetic canabinoid receptor agonists (SCRA). An updated harms assessment and a review of classification and scheduling under the Misuse of Drugs Act 1971 and its Regulations (October 2020)
Advisory Council on the Misuse of Drugs. Report - Novel Benzodiazepines - A review of the evidence of use and harms of Novel Benzodiazepines (April 2020)
Advisory Council on the Misuse of Drugs. Misuse of Fentanyl and Fentanyl Analogues (January 2020)
Home Office. Review of the Psychoactive Substances Act 2016 (November 2018)
